Open AccessEffects of denosumab treatment in chronic liver disease patients with osteoporosis
Author(s) -
Chisato Saeki,
Mitsuru Saito,
Tsunekazu Oikawa,
Masanori Nakano,
Yuichi Torisu,
Masayuki Saruta,
Akihito Tsubota
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i33.4960
Subject(s) - medicine , denosumab , osteoporosis , chronic liver disease , disease , gastroenterology , cirrhosis
Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease (CLD) patients. Denosumab has been shown to increase bone mineral density (BMD) and decrease the risk of osteoporotic fracture in the general population. However, there are few reports evaluating the efficacy of denosumab in CLD patients.